Benzinga | Sep 22, 2021 06:05AM EDT

HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $20

HC Wainwright & Co. analyst Oren Livnat maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and lowers the price target from $24 to $20.